Cetuximab N01

西妥昔单抗N01

Report date: 2026/05/13 20:02:10

Base Information

Drug NameCetuximab N01
Drug Alias NameRecombinant anti-EGFr antibody (Kelun Group)西妥昔单抗生物仿制药（科伦集团）西妥昔单抗生物类似物（科伦集团）Cetuximab biosimilar (Kelun Group)西妥昔单抗生物类似药（科伦集团） +[11] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsRectal NeoplasmsColorectal NeoplasmsCholangiocarcinoma +[5] 
Global Approved IndicationsColorectal Neoplasms
Approved Indications in ChinaColorectal Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2025/01/24
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSichuan Kelun Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer CenterSichuan Kelun-Biotech Biopharmaceutical Co Ltd
Inactive CompaniesSichuan Kelun Pharmacy Institute Co Ltd
Active IndicationsRectal NeoplasmsColorectal NeoplasmsCholangiocarcinoma +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeL01XC06
Related LinksWikipediaDrugBankKEGG